Overview

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 2 study of Pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Gemcitabine
Irinotecan
Leucovorin
Oxaliplatin
Paclitaxel
Pembrolizumab